Share This Page
Drugs in ATC Class C09C
✉ Email this page to a colleague
Subclasses in ATC: C09C - ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
C09C Market Analysis and Financial Projection
The angiotensin II receptor blockers (ARBs) market under ATC class C09C demonstrates dynamic growth intertwined with evolving patent landscapes and shifting therapeutic applications. Here's a comprehensive analysis:
Market Dynamics
Growth Projections and Drivers
- The global ARBs market is projected to grow from $8.51B in 2024 to $10.76B by 2029 (CAGR: 5%)[1][7], fueled by:
- Rising cardiovascular disease burden: By 2060, U.S. heart disease risks are expected to surge, driving demand for hypertension management[1].
- Chronic kidney disease (CKD) applications: ARBs like losartan and valsartan reduce proteinuria and slow CKD progression, with UK cases projected to rise 4% by 2032[7].
- Aging populations: Over 20% of adults >60 globally have hypertension, necessitating long-term therapies[4].
Generic Competition and Pricing Pressures
- Generics dominate >90% of U.S. prescriptions, pressuring branded ARB prices[4]. This is exacerbated by:
- Patent expirations: Most ARB patents expired post-2010, enabling generic entrants[2].
- Market fragmentation: While ACE inhibitors (e.g., ramipril) saw earlier genericization, ARB competition remains API-focused rather than brand-driven[2].
Regional Trends
- Asia-Pacific growth: India’s healthcare budget surged 137% in 2021, improving access to generics[4].
- Western Europe: Preference anchoring persists for older ACE inhibitors due to entrenched prescribing habits[2].
Patent Landscape
Therapeutic Expansion
- Cancer treatment: Patent WO2016141476A1 covers ARBs (e.g., irbesartan) for tumors with AT1R overexpression[3].
- Fibrotic diseases: US20220401416A1 details topical ARBs for fibrosis treatment[10].
Challenges and Litigation
- Biosimilar competition: ADC-related patents (e.g., vedotin) highlight complex litigation strategies, including licensing (e.g., Genentech’s Kadcyla®)[9].
- Safety controversies: EMA’s 2018 nitrosamine impurity warnings impacted ARB prescriptions[4].
Key Players
Major innovators include Novartis, Merck, and AstraZeneca, though generics dominate. Recent R&D focuses on:
- Combination therapies: Valsartan/amlodipine/hydrochlorothiazide combinations (ATC: C09DX)[8].
- Digital health tools: Apps improving medication adherence[5].
ATC Class C09C Breakdown
| Drug (ATC Code) | DDD | Key Brands |
|---|---|---|
| Losartan (C09CA01) | 50 mg | Cozaar® |
| Valsartan (C09CA03) | 80 mg | Diovan® |
| Telmisartan (C09CA07) | 40 mg | Micardis® |
Source: WHO ATC/DDD Index[6][15]
Future Outlook
- Precision medicine: Biomarker-guided ARB use may reduce adverse effects like hyperkalemia[5].
- Telemedicine adoption: Remote hypertension monitoring could boost ARB adherence[1].
- Biosimilars: Emerging competition may further lower prices post-2030[7].
"The surge in generics has reshaped ARB accessibility, but innovation in combination therapies and repurposing for oncology will redefine market boundaries." – Verified Market Research Analysis[4].
This landscape underscores a balance between generic-driven affordability and niche innovation, positioning ARBs as enduring tools in global cardiovascular care.
References
- https://www.openpr.com/news/3890912/prominent-angiotensin-receptor-blockers-arbs-market-trend
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8465659/
- https://patents.google.com/patent/WO2016141476A1/en
- https://www.verifiedmarketresearch.com/product/angiotensin-receptor-blockers-arbs-market/
- https://www.thebusinessresearchcompany.com/market-insights/global-angiotensin-receptor-blockers-arbs-market-2024
- https://atcddd.fhi.no/atc_ddd_index/?code=C09
- https://www.researchandmarkets.com/reports/5790618/angiotensin-receptor-blockers-arbs-market-report
- https://en.wikipedia.org/wiki/ATC_code_C09
- https://www.fbrice.com.au/ip-news-insights/traversing-a-dynamic-adc-patent-landscape-2/
- https://patents.google.com/patent/US20220401416A1/en
- https://www.ftc.gov/sites/default/files/documents/reports/generic-drug-entry-prior-patent-expiration-ftc-study/genericdrugstudy_0.pdf
- https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3587377
- https://www.uspto.gov/web/patents/classification/cpc/html/cpc-C09C.html
- https://patents.google.com/patent/CA1322069C/en
- https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=C09CA
More… ↓
